American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
Walsh
Patrick C
PC
D000728:Androgens / Q000502:physiology*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood; D018592:Cross-Over Studies; D004054:Diethylstilbestrol / Q000008:administration & dosage*; D018450:Disease Progression; D004340:Drug Contamination; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000473:pathology; D008517:Phytotherapy; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000728:Androgens; D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D004365:Drugs, Chinese Herbal; C114209:herbal preparation PC-SPES; D004054:Diethylstilbestrol; D017430:Prostate-Specific Antigen